Contracts › 75F40126C00096
75F40126C00096: Eo-14398-A Long-Term Vascular Mps to Assess Cyclic Cardiovascular Toxicity of Oncology Drugs
Awarded to Brigham & Womens Hospital Inc by Food and Drug Administration (FDA).
$1.5Mobligated
$3.0Mpotential value
29 September 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40126C00096 |
|---|---|
| Awardee | Brigham & Womens Hospital Inc |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AJ11 General Science and Technology R&D Services; General Science and Technology; Basic Research |
| Place of performance | MA |
| Offers received | 257 |
| Period of performance | 30 September 2026 to 29 September 2028 |
| Potential end | 29 September 2030 |
| Estimated recompete solicitation | ~Q2 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 13 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record